CoChat

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. METHODS: This non-interventional time and motion study was run in eight countries and 30 day oncology units. Rituximab SC data were collected alongside the MabCute trial (NCT01461928); IV data were collected per routine real-world practice. Trained observers recorded active HCP time for pre-specified tasks (stopwatch) and chair time (time of day). A random intercept model was used to analyze active HCP time (by task and for all tasks combined) in the treatment room and drug preparation area, drug administration duration, chair time and patient treatment room time by country and/or across countries. Active HCP and chair time were extrapolated to a patient's first year of treatment (11 rituximab sessions). RESULTS: Mean active HCP time was 35.0 and 23.7 minutes for IV and SC process, respectively (-32%, p <0.0001). By country, relative reduction in time was 27-58%. Absolute reduction in extrapolated active HCP time (first year of treatment) was 1.1-5.2 hours. Mean chair time was 262.1 minutes for IV, including 180.9 minutes infusion duration, vs. 67.3 minutes for SC, including 8.3 minutes SC injection administration (-74%, p <0.0001). By country, relative reduction was 53-91%. Absolute reduction in extrapolated chair time for the first year of treatment was 3.1-5.5 eight-hour days. CONCLUSIONS: Compared with rituximab IV, rituximab SC was associated with reduced chair time and active HCP time. The latter could be invested in other activities, whereas the former may lead to more available appointments, reducing waiting lists and increasing the efficiency of day oncology units. TRIAL REGISTRATION: ClinicalTrials.gov NCT01200758.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0157957

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Chronological listing of tasks measured. DPA tasks are in red and treatment room tasks are in blue. *Rituximab syringe can be filled either in the pharmacy (43%), or in a special aseptic DPA within the day oncology unit (57%). IV, intravenous; SC, subcutaneous; DPA, drug preparation area.
Fig 1 Chronological listing of tasks measured. DPA tasks are in red and treatment room tasks are in blue. *Rituximab syringe can be filled either in the pharmacy (43%), or in a special aseptic DPA within the day oncology unit (57%). IV, intravenous; SC, subcutaneous; DPA, drug preparation area.CC BY · PubMed Central
Fig 2 Active HCP time in treatment room and DPA (per session). HCP, health care professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.
Fig 2 Active HCP time in treatment room and DPA (per session). HCP, health care professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.CC BY · PubMed Central
Fig 3 Active HCP time in treatment room and DPA, by task (per session). The mean country estimate for each task is provided in S4 Table. Total active HCP time for IV administration in the UK was 79.5 minutes. HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.
Fig 3 Active HCP time in treatment room and DPA, by task (per session). The mean country estimate for each task is provided in S4 Table. Total active HCP time for IV administration in the UK was 79.5 minutes. HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.CC BY · PubMed Central
Fig 4 Active HCP time in treatment room and DPA, by HCP type (11 sessions). HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.
Fig 4 Active HCP time in treatment room and DPA, by HCP type (11 sessions). HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.CC BY · PubMed Central
Fig 5 Patient chair time for IV vs. SC administration (per session). Results derived from the random intercept model: infusion time (France, Russia), injection administration time (France), IV patient chair time (France), SC patient chair time (France). All other results were derived from the standard regression analysis. IV, intravenous; SC, subcutaneous.
Fig 5 Patient chair time for IV vs. SC administration (per session). Results derived from the random intercept model: infusion time (France, Russia), injection administration time (France), IV patient chair time (France), SC patient chair time (France). All other results were derived from the standard regression analysis. IV, intravenous; SC, subcutaneous.CC BY · PubMed Central
Fig 6 Patient chair time for first year of treatment (11 sessions).
Fig 6 Patient chair time for first year of treatment (11 sessions).CC BY · PubMed Central
Fig 7 Impact of first vs. subsequent infusion on (A) infusion duration and (B) patient chair time.
Fig 7 Impact of first vs. subsequent infusion on (A) infusion duration and (B) patient chair time.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 1

  1. M Rummel, 2014, Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study, Haematologica (EHA annual congress abstracts), 99

Cited by

See all 117

Metadata

Authors
De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T.
Affiliations
  • United BioSource Corporation (United Kingdom) (GB)
  • Concordia University (CA)
  • Genentech (US)
  • Ospedale Policlinico San Martino (IT)
  • F. Hoffmann-La Roche AG (CH)
Venue
PLOS ONE
Published
2016-06-30
Volume
11
Issue
6
Pages
e0157957
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2472310215
Cited by
108
References
16
Citations by year
2026: 10 · 2025: 12 · 2024: 15 · 2023: 11 · 2022: 6 · 2021: 13 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 10 · 2016: 1
FWCI
9.68
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
F. Hoffman-La Roche
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Social Sciences › Decision Sciences › Management Science and Operations Research › Healthcare Operations and Scheduling Optimization
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
rituximab, subcutaneous administration, intravenous infusion, non-Hodgkin lymphoma, treatment efficiency
MeSH terms
Rituximab, Antineoplastic Agents, Humans, Infusions, Intravenous, Injections, Subcutaneous, Lymphoma, Non-Hodgkin, Time and Motion Studies, Time Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries. https://app.cochat.ai/papers/10.1371/journal.pone.0157957
The paper
De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T. (2016). Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries. PLOS ONE. https://doi.org/10.1371/journal.pone.0157957

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.